FibroScan® 402
POWERED BY VCTE™
THE ESSENTIAL tool for liver stiffness measurement
FibroScan® 402
THE ESSENTIAL tool for liver stiffness measurement

A ROBUST TECHNOLOGY
Vibration-Controlled Transient Elastography (VCTE™)

→ Assess liver stiffness
→ Provide reproducible and operator independent examination
→ Explore a large volume (100 times larger than the biopsy)

EASY TO USE & TO INTEGRATE into your routine practice

→ Quantitative & immediate result in kPa
→ Plug & play device
→ Start your training online

LIVER STIFFNESS DETERMINES THE PATHOLOGICAL STATE

Soft liver = normal
Stiff liver = pathological state

FibroScan® measures liver stiffness that is directly related to liver conditions such as fibrosis, inflammation.

An extra clinical CONFIDENCE

→ Same technology as FibroScan® 502
→ Established clinical data
An extra clinical confidence → same technology as Fibroscan® 502 → established clinical data

- lighT & easy to handle device
- User-friendly TOUCH-SCREEN INTERFACE
- INTEGRATED printer
- ERGONOMIC probe
- LIGHT & EASY to handle device
- Touch-screen Interface
- Integrated Printer
- Ergonomic Probe
- User-friendly Touch-screen Interface
**TECHNICAL parameters**

**FibroScan® 402**

- Size: 275 x 434 x 252 mm (H x D x W)
- Weight: 8 kg
- Power: 100 - 230 Volts (+10%/-15%)
- Connection: Ethernet, USB, Video (DVI)
- Dedicated software
- Touch screen display: 10.4"

**PROBE**

- Size: 158 x 52 mm (L x Ø)
- Weight: 0.5 kg
- Transducer diameter: 7 mm
- Frequency: 3.5 MHz
- Cable: 1.5 m
- Connection: Push Pull

**OPTION**

- Compatible with Desk Solution, a FibroScan® review software

---

**RECOMMENDATIONS FOR USE**

- Training: Echosens or its representative must certify the operator to ensure the proper use of the device and all its features
- Examination procedures: 10 valid stiffness measurements at the same measurement point

**PRECAUTIONS FOR USE**

- FibroScan® should not be used on pregnant women, patients with active implantable medical devices and person with ascites
- Presence of ascites may prevent from obtaining valid measurements

---

**BIBLIOGRAPHY**


FS40220092012EN - Revision date 20/09/2012 - FibroScan® is a class IIa medical device according to Directive EC/93/42 and is manufactured by Echosens. Assessment of its conformity with the essential requirements of the Directive EC/93/42 is established by the LNE-G-MED (France). FibroScan® is indicated for the non-invasive measurement of liver stiffness (E) in adult human beings.

It is expressly recommended to closely read the instruction of the users’ guide and labeling of the device. FibroScan® examination must be performed only by operator certified by the manufacturer or its accredited local representative. FibroScan® must not be used in the following situation: other organs but liver, patients with active implantable medical devices (such as pacemaker, defibrillators, pump, etc.), wound at the measurement point, pregnant women. Presence of ascites can prevent from obtaining valid measurements. The values obtained with FibroScan® must be interpreted by a physician experienced in dealing with liver disease, taking into account the complete medical record of the patients.

In France, liver stiffness measurement by FibroScan® is included on the list of acts and services covered by the national Social Security medical insurance under the code HLQM002 and the following conditions. Indications: assessment of chronic untreated hepatitis C adult patients with HIV coinfection except obvious diagnosis of cirrhosis. Invoicing note: Within the limit of one examination per year except in case of risk factors of rapid evolution toward cirrhosis, if this new examination is expected to have an impact on the therapeutic management of the patient. In case of chronic hepatitis C: as second line test (in case of non agreement between the first line test and the clinical context or in case of non interpretable first line test) as an alternative to liver biopsy. In case of HIV-HCV coinfection: as first line test to evaluate the presence of cirrhosis. Environment: consultation specialized in the management of patients with HCV, in collaboration with a center specialized in the management of the HIV infection for the second indication.